Bifogade filer
Labema Oy places its first ASTar order
Kurs
-3,67%
Likviditet
0,69 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-10-30 | 07:30 | Kvartalsrapport 2026-Q3 |
| 2026-07-10 | 07:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-27 | N/A | Årsstämma |
| 2026-04-30 | 07:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-06 | 07:30 | Bokslutskommuniké 2025 |
| 2025-10-29 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-07-14 | - | Split QLINEA 1000:1 |
| 2025-07-10 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-26 | - | Årsstämma |
| 2025-05-23 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2025-04-14 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-03 | - | Extra Bolagsstämma 2025 |
| 2025-02-28 | - | Bokslutskommuniké 2024 |
| 2024-11-05 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-11 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | Årsstämma |
| 2024-06-12 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2024-05-31 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-13 | - | Kvartalsrapport 2023-Q2 |
| 2023-07-03 | - | Extra Bolagsstämma 2023 |
| 2023-06-13 | - | Årsstämma |
| 2023-05-24 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-14 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-26 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2021-05-25 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-18 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2019-05-22 | - | Årsstämma |
| 2019-05-03 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Q-linea AB (publ) (OMX: QLINEA) today announces that the company has received an order for an ASTar System from its distribution partner in Finland and the Baltics, Labema Oy.
“Our partner, Labema Oy, is preparing for the first installation at a hospital who wants to understand how ASTar can improve their workflows and patient outcome,” said Thomas Fritz, CCO at Q-linea. “From an international perspective, the levels of antimicrobial resistance (AMR) are low in the Nordic countries. However, AMR is a global cross-border health threat, and rapid AST can have multiple positive impacts on patient outcomes.”
About ASTar Instrument and ASTar BC G- Kit
ASTar Instrument and ASTar BC G- Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.
ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.
For more information, please contact:
Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60
Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20
About Q-linea
Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.